Van Tuyl Christopher 4

What Happened
Christopher Van Tuyl, Chief Legal Officer of Immunovant, reported sales of 1,206 shares on July 8, 2026, for total proceeds of approximately $47,702. The filing shows two groups: 1,143 shares sold for $45,183 (weighted avg $39.53) and 63 shares sold for $2,519 (weighted avg $39.99). These sales were executed to satisfy tax withholding obligations related to the vesting and settlement of RSUs and were not discretionary trades by the reporting person.

Key Details

• Transaction date: July 8, 2026; Form 4 filed July 10, 2026 (timely filing).
• Shares sold: 1,143 @ weighted avg $39.53 (range $38.91–$39.89) and 63 @ weighted avg $39.99 (range $39.92–$40.03). Total sold = 1,206 shares for ~$47,702.
• Reason: Sell-to-cover to satisfy tax withholding on RSUs granted April 1, 2025; 3,174 RSUs vested July 1, 2026 (footnote F1). The sale was mandated by the issuer’s sell-to-cover election (F1).
• Price details: weighted average prices reported; reporting person will provide per-price breakdown on request (F2, F3).
• Shares owned after transaction: not specified in the summary provided here—see the Form 4 for exact post-transaction holdings.

Context

• This was a tax-withholding sale tied to RSU vesting (routine), not a market-timing or discretionary sale signal. Retail investors often treat mandatory sell-to-cover transactions differently than voluntary insider sales when assessing insider sentiment.